GODREJAGRO Godrej Agrovet Q1 FY27 results (Apr–Jun 2026) and concall
Godrej Agrovet Limited reported a resilient Q1 FY27 with 10% consolidated sales growth to ₹2,852 crores, driven by strong performances in Animal Nutrition and Oil Palm. Astec LifeSciences achieved EBITDA breakeven, marking a significant recovery. However, the Crop Care segment faced headwinds from delayed monsoons, leading to a 16.2% revenue decline, while Dairy and Godrej Foods profitability was impacted by input cost inflation and geopolitical tensions. The company is actively pursuing strategic shifts in Oil Palm, Dairy, and Godrej Foods towards higher-margin, value-added products and B2C f
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 9.9%, net profit up 8.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,848 | 1,869 | 1,550 | 2,007 | 2,000 +8% | 2,070 +11% | 1,668 +8% | 2,205 +10% |
| EBITDA | 222 | 195 | 130 | 259 | 196 −12% | 212 +9% | 105 −19% | 228 −12% |
| Net profit | 132 | 166 | 68 | 169 | 177 +34% | 116 −30% | 65 −4% | 184 +9% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





